An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

NCT05594147 · clinicaltrials.gov ↗

COMPLETED

Status

4103

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumors
Coronavirus Disease 2019 (COVID-19)
SARS-CoV-2 Infection

Interventions

DRUG: Non-TKIs
DRUG: Other TKIs
DRUG: Regorafenib (Stivarga, BAY73- 4506)
DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer